Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma

Melanoma Research

Volumn 23, Issue 1, 2013, Pages 47-54

  Bernardo, Sebastian G ^a   Moskalenko, Marina ^a   Pan, Michael ^a   Shah, Shaily ^a   Sidhu, Harleen K ^a   Sicular, Serge ^a   Harcharik, Sara ^a   Chang, Rui ^a   Friedlander, Philip ^a   Saenger, Yvonne M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatotoxicity; Immunotherapy; Ipilimumab; Melanoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CORTICOTROPIN; DACARBAZINE; IPILIMUMAB; THYROTROPIN;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; COLITIS; CONSTIPATION; CORTICOTROPIN BLOOD LEVEL; CRYOTHERAPY; DIARRHEA; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTRANSAMINASEMIA; HYPOPHYSITIS; HYPOPITUITARISM; HYPOTHYROIDISM; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; METASTATIC MELANOMA; NAUSEA; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SYSTEMIC THERAPY; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE; VOMITING;

ALANINE TRANSAMINASE; ANTIBODIES, MONOCLONAL; ASPARTATE AMINOTRANSFERASES; CHI-SQUARE DISTRIBUTION; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 84872063180     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32835c7e68     Document Type: Article

References (19)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002 CA Cancer J Clin 2005; 55:74-108
2. Balch CM, Gershenwald JE, Soong S-J, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-6206
3. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4 mediated inhibition in regulation of T-cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001; 19:565-594 (Pubitemid 32368046)
4. Lipson EJ, Drake CG. Ipilimumab: An anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011; 17:6958-6962
5. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15:5591-5598
6. Patel SP,Woodman SE. Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther 2011; 5:489-495
7. Hodi FS, O'Day SJ, McDermot DF,Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723
8. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526
9. James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, et al. Measuring response in solid tumors: Unidimensional versus bidimensional measurement. J Natl Cancer Inst 1999; 91:523-528 (Pubitemid 29157060)
10. Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005; 28:593-598 (Pubitemid 41533093)
11. Farolfi A, Ridolfi L, Guidoboni M, Nicoletti SV, Piciucchi S, Valmorri L, et al. Ipilimumab in advanced melanoma: Reports of long-lasting responses. Melanoma Res 2012; 22:263-270
12. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13:6681-6688 (Pubitemid 350206804)
13. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043-6053
14. Bouwhuis MG, Ten Hagen TL, Suciu S, Eggermont AM. Autoimmunity and treatment outcome in melanoma. Curr Opin Oncol 2011; 23:170-176
15. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24:2283-2289 (Pubitemid 46630658)
16. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-164
17. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti- CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37: 499-507
18. Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 2011; 29:489-498
19. Di Giacomo AM, Danielli R, Calabro L, Bertocci E, Nannicini C, Giannarelli D, et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother 2011; 60:467-477